Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Massachusetts Life Sciences Center (MLSC) has awarded $1m grant to an ongoing collaboration between the University of Massachusetts Medical School (UMMS) and RXi Pharmaceuticals to develop a new treatment for amyotrophic lateral sclerosis (ALS) using sd-rxRNA - RXI’s proprietary self-delivering RNAi therapeutic platform.
Subscribe to our email newsletter
The MLSC grant amount is $250,000 per year for two years, and subject to a formalized agreement between the parties, will be matched dollar for dollar by RXi, totaling to up to $500,000 in funding for this project.
The work focuses on delivery to the spinal cord and brain to silence the SOD1 gene in ALS.
Completion of the project is expected to generate supportive data for clinical development of anti-SOD1 sd-rxRNA therapy.
Bob Brown will be the principal investigator at UMMS leading this project.
RXi Pharmaceuticals president and CEO Mark Ahn said this grant underwent rigorous review by the Life Sciences Center’s Scientific Advisory Board and recognizes the potential of RXi’s technology to advance novel treatments for ALS.